Systemic Sclerosis Drug Sales

Systemic Sclerosis Drug Sales Market Outlook

The global systemic sclerosis drug sales market is projected to reach USD 6.5 billion by 2035, with a compound annual growth rate (CAGR) of approximately 7.4% during the forecast period of 2025 to 2035. The increasing prevalence of systemic sclerosis, coupled with the rising awareness of the disease, is driving market growth. Additionally, advancements in drug development and therapies, including biologics and targeted treatments, are expected to enhance treatment efficacy, providing significant momentum to the market. The growing investment in research and development from pharmaceutical companies to innovate new drugs is another crucial factor anticipated to propel the market forward. Furthermore, the increasing geriatric population, which is more susceptible to autoimmune diseases, contributes substantially to the rising demand for systemic sclerosis treatments, thereby expanding market opportunities.

Growth Factor of the Market

The systemic sclerosis drug sales market is largely driven by several factors, one of which includes the increasing incidence of systemic sclerosis worldwide. This autoimmune disease affects connective tissues, leading to severe complications that necessitate effective treatment options. The growing number of clinical trials focusing on systemic sclerosis therapies is indicative of a robust pipeline that can cater to unmet medical needs, thus stimulating market growth. Moreover, the high level of investment from both public and private sectors in healthcare is aimed at enhancing the quality of life for patients suffering from chronic diseases, including systemic sclerosis. The shift towards personalized medicine, where treatment options are tailored to individual patient needs, is also a promising trend that is expected to revolutionize the treatment landscape. Additionally, the rise of patient advocacy groups has increased awareness and funding for systemic sclerosis research, further contributing to market expansion.

Key Highlights of the Market

• The global systemic sclerosis drug sales market is expected to reach USD 6.5 billion by 2035.
• A CAGR of 7.4% is projected from 2025 to 2035.
• The rising prevalence of systemic sclerosis is a primary driver of market growth.
• Advancements in drug development and biologics are enhancing treatment options.
• The increasing geriatric population is contributing to the demand for systemic sclerosis treatments.

By Drug Type

Immunosuppressants:

Immunosuppressants are pivotal in the management of systemic sclerosis, primarily used to mitigate the immune response that characterizes the disease. These drugs work by inhibiting the activity of the immune system, thereby reducing inflammation and preventing further tissue damage. The increasing adoption of immunosuppressants in clinical settings is largely attributable to their effectiveness in managing autoimmune symptoms and slowing disease progression. With continuous advancements in formulations and delivery mechanisms, the market for immunosuppressants is set to grow. Such enhancements are critical as they not only improve patient compliance but also optimize drug efficacy. Furthermore, ongoing research into novel immunosuppressive agents presents considerable opportunities for market growth, as healthcare providers continuously seek more effective treatments to improve patient outcomes in systemic sclerosis.

Corticosteroids:

Corticosteroids have been a cornerstone in the treatment of systemic sclerosis, primarily due to their potent anti-inflammatory properties. They help to manage acute exacerbations of the disease and provide symptomatic relief to patients. The corticosteroid market segment is anticipated to grow as physicians often prescribe these medications to control inflammation and prevent further complications in systemic sclerosis patients. Given their effectiveness, corticosteroids can enhance patient quality of life, making them a valuable component of comprehensive treatment regimens. However, the long-term use of corticosteroids can lead to significant side effects, leading to a shift towards more targeted therapies. Nevertheless, the demand for corticosteroids remains strong, particularly for short-term treatment courses or in conjunction with other therapies, underscoring their importance in the systemic sclerosis drug sales market.

Endothelin Receptor Antagonists:

Endothelin receptor antagonists are increasingly utilized in the treatment of systemic sclerosis, particularly for managing pulmonary arterial hypertension, a common complication associated with the disease. These drugs function by blocking the effects of endothelin, a powerful vasoconstrictor that can exacerbate vascular complications in patients. Their ability to improve hemodynamics and exercise capacity has made endothelin receptor antagonists a vital option for clinicians treating systemic sclerosis patients. As awareness increases regarding the importance of managing vascular complications in systemic sclerosis, the market for these agents is likely to expand. Moreover, clinical data supporting the efficacy of endothelin receptor antagonists is continuously evolving, providing a solid foundation for their integration into treatment protocols, thus driving their market growth.

Prostacyclin Analogues:

Prostacyclin analogues have emerged as a critical treatment option for patients with systemic sclerosis, particularly those who develop pulmonary hypertension. These medications act as potent vasodilators, improving blood flow and reducing the severity of pulmonary hypertension. The growing recognition of the importance of early intervention in managing pulmonary complications has bolstered the sales of prostacyclin analogues within the systemic sclerosis drug sales market. As clinical outcomes improve with the introduction of more stable prostacyclin formulations, patient adherence to treatment regimens is expected to enhance, contributing to market growth. The ongoing research and development efforts aimed at improving the pharmacokinetics and administration routes of prostacyclin analogues further underline their potential for success in treating systemic sclerosis and related complications.

Calcium Channel Blockers:

Calcium channel blockers are commonly prescribed to patients suffering from systemic sclerosis, specifically to manage symptoms associated with Raynaud’s phenomenon, a condition that often accompanies the disease. These medications work by relaxing blood vessels, thereby improving blood flow and reducing symptoms. The rising prevalence of Raynaud’s phenomenon among systemic sclerosis patients has driven the demand for calcium channel blockers, establishing a significant segment within the market. Their relatively favorable safety profile and effectiveness in symptom management have made them a preferred choice among healthcare providers. Additionally, as healthcare professionals become more adept at recognizing and treating the vascular aspects of systemic sclerosis, the market for calcium channel blockers is anticipated to experience continued growth, making it a key player in the systemic sclerosis drug sales market.

By Route of Administration

Oral:

Oral administration remains the most prevalent route for delivering systemic sclerosis drugs, primarily due to its convenience and ease of use for patients. Many systemic sclerosis medications, including immunosuppressants and corticosteroids, are available in oral formulations, allowing for flexible dosing regimens that can be tailored to individual patient needs. This method is particularly appealing for long-term management of chronic conditions, as it enables patients to self-administer medications at home without the need for professional assistance. The increasing preference for oral formulations can also be attributed to advancements in drug delivery technologies that enhance bioavailability and patient compliance. As the systemic sclerosis drug sales market continues to evolve, oral administration is likely to remain a dominant route due to its favorable characteristics, which facilitate consistent and effective treatment.

Injectable:

Injectable routes of administration are critical for delivering certain systemic sclerosis treatments, particularly when immediate therapeutic effects are required or when oral administration is not feasible. This route includes both subcutaneous and intravenous injections, which provide rapid absorption of medications, thereby ensuring quick relief of symptoms. Injectable formulations are commonly used for biologics and some immunosuppressants, making them an essential component of comprehensive treatment plans. With ongoing advancements in injection technologies, such as pre-filled syringes and auto-injectors, patient compliance and experience are significantly improved. As healthcare providers increasingly recognize the benefits of injectable therapies in managing systemic sclerosis, this segment is expected to witness robust growth in the coming years, reflecting the broader trend towards more effective and convenient treatment options.

Topical:

Topical administration is gaining traction in the systemic sclerosis drug sales market, particularly for managing localized symptoms such as skin changes and ulcers. Topical treatments, including creams and ointments, offer targeted relief with minimal systemic side effects, making them a desirable option for patients. This route is particularly advantageous in addressing the skin manifestations of systemic sclerosis, providing symptomatic relief without the need for systemic medications. The development of specialized topical formulations aimed at improving skin hydration and integrity has driven further interest in this route of administration. As patient preferences shift towards more localized treatment options, the market for topical formulations is anticipated to expand, underscoring the importance of developing innovative solutions tailored to the unique challenges faced by systemic sclerosis patients.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a crucial role in the distribution of systemic sclerosis drugs, particularly for patients requiring complex therapies or those admitted for acute care. These pharmacies are typically equipped to handle high-demand medications and can provide comprehensive pharmaceutical care, including patient counseling and monitoring. The presence of specialized healthcare professionals within hospital settings allows for a more tailored approach to medication management, ensuring that patients receive the most appropriate therapies for their specific conditions. As the prevalence of systemic sclerosis continues to rise, hospital pharmacies are expected to maintain a significant market share, driven by the increasing need for specialized care and the growing complexity of treatment regimens. Furthermore, the collaboration between hospital pharmacies and healthcare providers enhances the overall patient experience, facilitating improved outcomes and satisfaction.

Retail Pharmacies:

Retail pharmacies are a vital distribution channel for systemic sclerosis drugs, providing patients with convenient access to their medications. These pharmacies offer a range of systemic sclerosis treatments, including oral medications and topical formulations, making them accessible to patients in community settings. The increasing trend towards outpatient care has further solidified the role of retail pharmacies in the healthcare landscape, as more patients manage their conditions at home rather than in clinical settings. Additionally, retail pharmacies often provide ancillary services, such as medication synchronization and adherence programs, which can enhance patient compliance and therapeutic outcomes. As patients increasingly turn to retail outlets for their medication needs, this distribution channel is expected to grow, reflecting the broader shift towards patient-centered care and convenience in the healthcare system.

Online Pharmacies:

Online pharmacies have emerged as an increasingly popular distribution channel for systemic sclerosis drugs, driven by the growing demand for convenience and accessibility in healthcare. The rise of e-commerce platforms has transformed the way patients access their medications, allowing them to order prescriptions from the comfort of their homes. This trend is particularly beneficial for systemic sclerosis patients, who may face mobility challenges or require ongoing treatment. Online pharmacies often provide competitive pricing, home delivery services, and access to specialized medications that may not be readily available at brick-and-mortar locations. As the digital landscape continues to evolve, the market for online pharmacies is anticipated to expand, providing a valuable alternative for systemic sclerosis patients seeking accessible and efficient medication management.

By User

Hospitals:

Hospitals are key users of systemic sclerosis drugs, particularly for patients requiring acute management or complex therapies. The healthcare professionals within hospitals are equipped to handle the specific needs of systemic sclerosis patients, ensuring appropriate medication selection and administration. Hospitals typically utilize a range of systemic sclerosis treatments in their formulary, including immunosuppressants, corticosteroids, and biologics, to address the multifaceted nature of the disease. As the prevalence of systemic sclerosis continues to rise, hospitals are likely to see an increase in demand for these medications, further solidifying their role as a critical user within the systemic sclerosis drug sales market. Additionally, hospitals often conduct clinical trials and research initiatives, contributing to the advancement of treatment options and enhancing patient care.

Clinics:

Clinics represent an essential user segment for systemic sclerosis drugs, particularly outpatient facilities focused on managing chronic conditions. These healthcare settings often provide ongoing care and support for patients with systemic sclerosis, including regular monitoring, medication management, and patient education. Clinics typically utilize a variety of systemic sclerosis treatments, enabling them to customize care based on individual patient needs. The rise of specialized clinics dedicated to autoimmune diseases is anticipated to drive further demand for systemic sclerosis drugs, as patients seek comprehensive management options. Additionally, the collaborative approach taken by clinics, involving interdisciplinary teams of healthcare professionals, enhances the overall quality of care and ensures that patients receive the most effective therapies available.

Homecare:

Homecare services are becoming an increasingly important user segment in the systemic sclerosis drug sales market, as more patients are managing their conditions from home. Homecare allows patients to receive ongoing treatment and support in a familiar environment, which can enhance their overall well-being and quality of life. The use of systemic sclerosis medications in homecare settings often includes oral therapies and topical treatments, which are easier to administer outside of clinical environments. Moreover, healthcare professionals provide vital education and monitoring to patients and their families, ensuring that treatment regimens are followed effectively. The growing trend towards homecare services, compounded by advancements in telemedicine and remote monitoring technologies, is expected to significantly impact the market, as patients increasingly prefer the convenience and personalized care that these services offer.

By Region

North America is currently the largest market for systemic sclerosis drugs, driven by a well-established healthcare infrastructure and increased awareness of the disease. The region is projected to account for approximately 45% of the global market share by 2035, with a CAGR of 7.1% during the forecast period. Factors such as high healthcare expenditure, availability of advanced treatment options, and a growing population of geriatric patients contribute to the region's dominance in the market. Additionally, the presence of major pharmaceutical companies and ongoing research initiatives in North America bolster the development and availability of innovative systemic sclerosis therapies. These factors highlight the region's potential for sustained growth, making it a focal point for systemic sclerosis drug sales.

In Europe, the systemic sclerosis drug sales market is anticipated to exhibit significant growth, driven by increasing prevalence rates and a rising focus on autoimmune diseases. The European market is expected to capture around 25% of the global market share by 2035, with a projected CAGR of 6.8% during the same period. The growing number of specialized clinics and healthcare facilities dedicated to treating systemic sclerosis further enhances access to effective therapies. Additionally, the collaborative efforts among various stakeholders in the region, including pharmaceutical companies, healthcare providers, and patient advocacy groups, are expected to foster advancements in treatment options and improve patient care. As European countries continue to prioritize autoimmune disease research, the systemic sclerosis drug sales market is poised for growth and development.

Opportunities

The systemic sclerosis drug sales market presents substantial opportunities for growth, primarily driven by the increasing demand for innovative treatment options. As more pharmaceutical companies invest in research and development, the introduction of novel drugs and therapies tailored to systemic sclerosis is expected to reshape the market landscape. This focus on innovation is crucial, as existing treatment options may not adequately address all aspects of the disease, leading to the need for more effective solutions. Moreover, the rise of personalized medicine, which emphasizes customizing treatment regimens based on individual patient profiles, opens new avenues for tailored therapeutic approaches. Such advancements not only enhance patient outcomes but also create compelling market opportunities for companies willing to invest in the development of specialized systemic sclerosis drugs.

Another area of opportunity lies in the expansion of patient education and advocacy initiatives. Increased awareness of systemic sclerosis and its implications can drive market growth by encouraging patients to seek treatment earlier and adhere to prescribed therapies. In addition, the development of comprehensive care programs that integrate lifestyle management, symptom control, and emotional support can further enhance patient engagement and satisfaction. By empowering patients with knowledge and resources, stakeholders can create a more supportive environment for those living with systemic sclerosis, ultimately leading to improved treatment adherence and outcomes. As the market continues to evolve, leveraging these opportunities will be essential for companies aiming to establish a competitive edge in the systemic sclerosis drug sales arena.

Threats

Despite the promising growth opportunities in the systemic sclerosis drug sales market, several threats could impede progress. One of the primary challenges is the high cost associated with developing new drugs, which can be particularly prohibitive for smaller pharmaceutical companies. The lengthy and expensive process of clinical trials can limit the number of innovative therapies entering the market, potentially stifling competition. Furthermore, the increasing scrutiny from regulatory bodies regarding drug efficacy and safety can lead to delays in product approvals, hindering timely access to new treatments for patients who need them. Additionally, the presence of generic alternatives may pressure pricing and margins, impacting the financial viability of specialized systemic sclerosis treatments.

Restraining factors such as limited awareness of systemic sclerosis among healthcare providers and patients can also pose challenges to market growth. Many individuals may remain undiagnosed or misdiagnosed, resulting in delayed treatment and worse health outcomes. The lack of standardized treatment protocols for systemic sclerosis can lead to inconsistencies in care and hinder the effective utilization of available therapies. Efforts to improve education and training for healthcare professionals regarding the recognition and management of systemic sclerosis are essential to address these issues. Without concerted efforts to raise awareness and enhance treatment accessibility, the systemic sclerosis drug sales market may face obstacles in realizing its full potential.

Competitor Outlook

• Roche
• AbbVie
• Novartis
• Pfizer
• Sanofi
• Actelion Pharmaceuticals
• Bristol-Myers Squibb
• Amgen
• Gilead Sciences
• Teva Pharmaceuticals
• Celgene Corporation
• Merck & Co.
• Eli Lilly and Company
• Boehringer Ingelheim
• UCB Pharma

The competitive landscape of the systemic sclerosis drug sales market is characterized by the presence of several key players, each striving to establish a significant foothold. Companies such as Roche and AbbVie lead the charge with their extensive portfolios of autoimmune disease treatments, investing heavily in research and development to bring innovative solutions to market. Their existing pipeline of systemic sclerosis therapies reflects a robust commitment to addressing the unmet needs of patients suffering from this challenging condition. Furthermore, collaborations and partnerships among these companies often pave the way for accelerated research initiatives that can drive the development of novel therapies, ultimately enhancing patient care.

Novartis and Pfizer are also notable contenders in the systemic sclerosis space, focusing on developing targeted therapies that alleviate specific symptoms associated with the disease. Their efforts to incorporate patient feedback into drug development have resulted in more patient-centric solutions, addressing the multifaceted challenges faced by individuals living with systemic sclerosis. As these companies leverage cutting-edge technologies and scientific advancements, their contributions to the systemic sclerosis drug sales market are expected to be significant, driving growth and innovation.

Sanofi and Actelion Pharmaceuticals are actively involved in clinical research and trials aimed at expanding the treatment landscape for systemic sclerosis. They focus on discovering novel mechanisms of action and exploring new paths of therapy that can potentially revolutionize systemic sclerosis management. Their commitment to understanding the underlying biology of the disease positions them well to develop breakthrough therapies. As they navigate regulatory pathways and engage with stakeholders, these companies are expected to play a pivotal role in shaping the future of the systemic sclerosis drug sales market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Roche
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Pfizer
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Sanofi
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Novartis
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 UCB Pharma
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Gilead Sciences
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Celgene Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Boehringer Ingelheim
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Bristol-Myers Squibb
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Teva Pharmaceuticals
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Eli Lilly and Company
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Actelion Pharmaceuticals
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Systemic Sclerosis Drug Sales Market, By User
    • 6.1.1 Hospitals
    • 6.1.2 Clinics
    • 6.1.3 Homecare
  • 6.2 Systemic Sclerosis Drug Sales Market, By Drug Type
    • 6.2.1 Immunosuppressants
    • 6.2.2 Corticosteroids
    • 6.2.3 Endothelin Receptor Antagonists
    • 6.2.4 Prostacyclin Analogues
    • 6.2.5 Calcium Channel Blockers
  • 6.3 Systemic Sclerosis Drug Sales Market, By Distribution Channel
    • 6.3.1 Hospital Pharmacies
    • 6.3.2 Retail Pharmacies
    • 6.3.3 Online Pharmacies
  • 6.4 Systemic Sclerosis Drug Sales Market, By Route of Administration
    • 6.4.1 Oral
    • 6.4.2 Injectable
    • 6.4.3 Topical

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Systemic Sclerosis Drug Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Systemic Sclerosis Drug Sales market is categorized based on

By Drug Type

• Immunosuppressants
• Corticosteroids
• Endothelin Receptor Antagonists
• Prostacyclin Analogues
• Calcium Channel Blockers

By Route of Administration

• Oral
• Injectable
• Topical

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By User

• Hospitals
• Clinics
• Homecare

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Roche
• AbbVie
• Novartis
• Pfizer
• Sanofi
• Actelion Pharmaceuticals
• Bristol-Myers Squibb
• Amgen
• Gilead Sciences
• Teva Pharmaceuticals
• Celgene Corporation
• Merck & Co.
• Eli Lilly and Company
• Boehringer Ingelheim
• UCB Pharma